Almirall Clinical Study Shows Treatment Outcomes With Up To Five Years Of Lebrikizumab
Almirall has announced that its Phase 3B Adlong clinical study demonstrated treatment outcomes with up to five years of Lebrikizumab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Almirall shares new dermatology data at EADV 2026
The company said its programme at the 35th European Academy of Dermatology and Venereology Congress in Vienna includes more than 20 abstracts, late-breaking data and two expert symposia. It highlighted new evidence for lebrikizumab, tildrakizumab, CAL/BDP PAD cream and tirbanibulin across atopic dermatitis, psoriasis a